Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.

Stiborova M, Poljakova J, Eckschlager T, Kizek R, Frei E.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):115-21. doi: 10.5507/bp.2012.043.

2.

The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.

Poljaková J, Eckschlager T, Hrabeta J, Hrebacková J, Smutný S, Frei E, Martínek V, Kizek R, Stiborová M.

Biochem Pharmacol. 2009 May 1;77(9):1466-79. doi: 10.1016/j.bcp.2009.01.021. Epub 2009 Feb 13.

PMID:
19426684
3.

Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.

Poljakova J, Hrebackova J, Dvorakova M, Moserova M, Eckschlager T, Hrabeta J, Göttlicherova M, Kopejtkova B, Frei E, Kizek R, Stiborova M.

Neuro Endocrinol Lett. 2011;32 Suppl 1:101-16.

PMID:
22167207
4.

Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.

Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M.

Biochem Pharmacol. 2002 Jul 15;64(2):289-95.

PMID:
12123750
5.

Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.

Martinkova E, Dontenwill M, Frei E, Stiborova M.

Neuro Endocrinol Lett. 2009;30 Suppl 1:60-6.

PMID:
20027146
6.

The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.

Stiborová M, Sejbal J, Borek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudecek J, Wiessler M, Frei E.

Cancer Res. 2004 Nov 15;64(22):8374-80.

7.

Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.

Stiborova M, Rupertova M, Schmeiser HH, Frei E.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):13-23. Review.

8.

DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.

Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E.

Int J Cancer. 2003 Dec 20;107(6):885-90.

9.

The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells.

Poljaková J, Eckschlager T, Hřebačková J, Hraběta J, Stiborová M.

Interdiscip Toxicol. 2008 Sep;1(2):186-9. doi: 10.2478/v10102-010-0036-9.

10.

The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.

Stiborová M, Bieler CA, Wiessler M, Frei E.

Biochem Pharmacol. 2001 Dec 15;62(12):1675-84.

PMID:
11755121
11.

Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.

Hrabeta J, Groh T, Khalil MA, Poljakova J, Adam V, Kizek R, Uhlik J, Doktorova H, Cerna T, Frei E, Stiborova M, Eckschlager T.

Int J Oncol. 2015 Sep;47(3):971-80. doi: 10.3892/ijo.2015.3066. Epub 2015 Jun 29.

PMID:
26134421
12.

The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.

Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudecek J, Václavíková R, Frei E, Stiborová M.

Drug Metab Dispos. 2007 Oct;35(10):1926-34. Epub 2007 Jul 26.

13.

Ellipticine cytotoxicity to cancer cell lines - a comparative study.

Stiborová M, Poljaková J, Martínková E, Bořek-Dohalská L, Eckschlager T, Kizek R, Frei E.

Interdiscip Toxicol. 2011 Jun;4(2):98-105. doi: 10.2478/v10102-011-0017-7.

15.

Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.

Stiborová M, Rupertová M, Frei E.

Biochim Biophys Acta. 2011 Jan;1814(1):175-85. doi: 10.1016/j.bbapap.2010.05.016. Epub 2010 Jun 8. Review.

PMID:
20576524
16.

Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.

Stiborová M, Indra R, Moserová M, Cerná V, Rupertová M, Martínek V, Eckschlager T, Kizek R, Frei E.

Chem Res Toxicol. 2012 May 21;25(5):1075-85. doi: 10.1021/tx3000335. Epub 2012 Mar 15.

PMID:
22390216
17.

Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.

Stiborová M, Stiborová-Rupertová M, Borek-Dohalská L, Wiessler M, Frei E.

Chem Res Toxicol. 2003 Jan;16(1):38-47.

PMID:
12693029
18.

DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.

Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabeta J, Stiborová M.

Cancer Lett. 2007 Jul 18;252(2):270-9. Epub 2007 Feb 16.

PMID:
17306925
19.

Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.

Stiborová M, Rupertová M, Aimová D, Ryslavá H, Frei E.

Toxicology. 2007 Jul 1;236(1-2):50-60. Epub 2007 Apr 7.

PMID:
17482743
20.

Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.

Procházka P, Libra A, Zemanová Z, Hřebačková J, Poljaková J, Hraběta J, Bunček M, Stiborová M, Eckschlager T.

Cancer Sci. 2012 Feb;103(2):334-41. doi: 10.1111/j.1349-7006.2011.02137.x. Epub 2011 Nov 29.

Supplemental Content

Support Center